Skip to contentA
Agios Pharmaceuticals, Inc.
A
AGIOAgios Pharmaceuticals, Inc. Q4 2018 · 10-K
Revenue$30.01M$30.01M+206.3% vs Q4 2017 Net Income-$91.79M-$91.79MderivedN/M vs Q4 2017 EPS Diluted-$1.58-$1.58N/M vs Q4 2017 Operating Income-$96,356,000
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Agios Pharmaceuticals, Inc. · CIK 1439222 · Engraved from SEC EDGAR
N/M
Operating Cash Flowderived-$74,187,000N/M Free Cash Flowderived-$75,240,000N/M Margins · derivedOperating margin-321.0%+598.7 pt vs Q4 2017
Net margin-305.8%+595.1 pt vs Q4 2017
ended Dec 31, 2018 · filed Feb 14, 2019 · 45 d after period end